BIRMINGHAM, Ala.--(BUSINESS WIRE)--Circulogene Theranostics, the only biotechnology company able to enrich circulating cell-free DNA (cfDNA) from single-drop volumes of fluid, today announced the acceptance of four of its scientific abstracts for the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
